Literature DB >> 10951346

Evaluation of alternative methods of cervical cancer screening for resource-poor settings.

L Denny1, L Kuhn, A Pollack, H Wainwright, T C Wright.   

Abstract

BACKGROUND: Noncytologic methods of screening for cervical carcinoma and its precursor lesions are needed for resource-poor settings in which cervical carcinoma continues to be an important cause of morbidity and mortality.
METHODS: Two thousand nine hundred forty-four women ages 35-65 years were recruited from Cape Town, South Africa and screened using a combination of a Papanicolaou (Pap) smear, human papillomavirus (HPV) DNA testing, direct visual inspection after the application of a 5% acetic acid solution (DVI), and cervicography. Cervicography was considered primarily as a method with which to quality control the DVI examinations. Women with squamous intraepithelial lesions (SIL) or carcinoma on Pap smear, positive DVI examination (acetowhite lesion or cervical ulcer/growth), high levels of high risk HPV DNA (relative light units [RLU] > 10x positive control), or positive Cervigramtrade mark were referred for colposcopy and cervical biopsy.
RESULTS: Pap smears were positive in 8.1% of all women screened and identified 65 (78%) of all cases of biopsy confirmed high grade disease (high grade SIL or invasive carcinoma). DVI and cervicography were classified as positive in 18.1% and 10.5%, respectively, of women screened and identified 58 (67%) and 46 (58%) of all cases of high grade disease, respectively. The results of HPV DNA testing varied depending on the cutoff value used to define a positive result. At the standard cutoff level (RLU > 1x positive control), 16.2% of women screened were classified as high risk HPV DNA positive, as were 63 women with high grade disease (73%).
CONCLUSIONS: DVI and HPV DNA testing identified similar numbers of high grade SIL (cervical intraepithelial neoplasia Grade 2,3) and invasive carcinoma cases as Pap smears. However, both classify considerably more women without cervical disease as being test positive. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10951346     DOI: 10.1002/1097-0142(20000815)89:4<826::aid-cncr15>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  37 in total

1.  Andriod Device-Based Cervical Cancer Screening for Resource-Poor Settings.

Authors:  Vidya Kudva; Keerthana Prasad; Shyamala Guruvare
Journal:  J Digit Imaging       Date:  2018-10       Impact factor: 4.056

2.  eC3--a modern telecommunications matrix for cervical cancer prevention in Zambia.

Authors:  Groesbeck P Parham; Mulindi H Mwanahamuntu; Krista S Pfaendler; Vikrant V Sahasrabuddhe; Daniel Myung; Gracilia Mkumba; Sharon Kapambwe; Bianca Mwanza; Carla Chibwesha; Michael L Hicks; Jeffrey S A Stringer
Journal:  J Low Genit Tract Dis       Date:  2010-07       Impact factor: 1.925

3.  Measurements of human papillomavirus transcripts by real time quantitative reverse transcription-polymerase chain reaction in samples collected for cervical cancer screening.

Authors:  Laurence Lamarcq; James Deeds; David Ginzinger; Jean Perry; Siddhartha Padmanabha; Karen Smith-McCune
Journal:  J Mol Diagn       Date:  2002-05       Impact factor: 5.568

4.  Prevalence of human papilloma virus infection in women in rural Ethiopia.

Authors:  R Ruland; C Prugger; R Schiffer; M Regidor; R J Lellé
Journal:  Eur J Epidemiol       Date:  2006-10-27       Impact factor: 8.082

Review 5.  Optical imaging for cervical cancer detection: solutions for a continuing global problem.

Authors:  Nadhi Thekkek; Rebecca Richards-Kortum
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

6.  A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo.

Authors:  S Hovland; M Arbyn; A K Lie; W Ryd; B Borge; E J Berle; H Skomedal; T M Kadima; L Kyembwa; E M Billay; D Mukwege; R B Chirimwami; T M Mvula; P J Snijders; C J L M Meijer; F Karlsen
Journal:  Br J Cancer       Date:  2010-03-02       Impact factor: 7.640

7.  Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India.

Authors:  Patti E Gravitt; Proma Paul; Hormuzd A Katki; Haripriya Vendantham; Gayatri Ramakrishna; Mrudula Sudula; Basany Kalpana; Brigitte M Ronnett; K Vijayaraghavan; Keerti V Shah
Journal:  PLoS One       Date:  2010-10-28       Impact factor: 3.240

8.  Implementation of 'see-and-treat' cervical cancer prevention services linked to HIV care in Zambia.

Authors:  Mulindi H Mwanahamuntu; Vikrant V Sahasrabuddhe; Krista S Pfaendler; Victor Mudenda; Michael L Hicks; Sten H Vermund; Jeffrey S A Stringer; Groesbeck P Parham
Journal:  AIDS       Date:  2009-03-27       Impact factor: 4.177

9.  A population-based study of visual inspection with acetic acid (VIA) for cervical screening in rural Nigeria.

Authors:  Kayode Olusegun Ajenifuja; Julia C Gage; Akinfolarin C Adepiti; Nicolas Wentzensen; Claire Eklund; Mary Reilly; Martha Hutchinson; Robert D Burk; Mark Schiffman
Journal:  Int J Gynecol Cancer       Date:  2013-03       Impact factor: 3.437

10.  Cervical cancer screening among college students in ghana: knowledge and health beliefs.

Authors:  Peter N Abotchie; Navkiran K Shokar
Journal:  Int J Gynecol Cancer       Date:  2009-04       Impact factor: 3.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.